Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …

Whole-genome sequencing (WGS) permits comprehensive cancer genome analyses,
revealing mutational signatures, imprints of DNA damage, and repair processes that have …

Genomic instability is the hallmark of various cancers with the increasing accumulation of
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …

The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …

Age is the dominant risk factor for most chronic human diseases, but the mechanisms
through which ageing confers this risk are largely unknown. The age-related acquisition of …

Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …